News Releases:

2010

miRagen Therapeutics and t2cure Sign Licensing Agreement for microRNA Target Implicated in Vascular Disease

Agreement expands miRagen’s research and development, intellectual property in the field of microRNA-based therapeutics   BOULDER, Colo. and FRANKFURT, Germany, November 30, 2010 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA... View »

miRagen Therapeutics Signs Research and Licensing Agreements with University of Colorado for microRNA Profiling of Human Heart Failure Study

Data to expand miRagen’s research and development, intellectual property in the field of microRNA-based therapeutics BOULDER, Colo., October 26, 2010 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for... View »

miRagen Therapeutics’ Director of Biology to Give Plenary Lecture at Center for Heart Failure Research Symposium in Oslo, Norway

Talk to highlight compelling new data supporting antimiR-208 as a potential therapy for heart disease Boulder, CO, September 30, 2010 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for... View »

miRagen Therapeutics Announces Identification of a microRNA as Key Regulator of Blood Cell Development

Findings illustrate crucial role of miR-451 in the process of blood cell maturation and offer promising avenue for therapeutic intervention in myeloproliferative diseases Data published in the latest issue of Genes & Development BOULDER, Colo., July 31, 2010 –... View »

Santaris Pharma A/S and miRagen Therapeutics, Inc. Form Strategic Alliance to Develop microRNA-targeted Medicines for the Treatment of Cardiovascular Disease

miRagen licenses rights to utilize Santaris Pharma A/S proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against miRagen’s proprietary microRNA targets for the treatment of cardiovascular disease Santaris Pharma A/S obtains a minority equity... View »

miRagen’s Director of Biology to Give Keynote Lecture at The Ohio State University College of Pharmacy’s Research Day & Symposium

Presentation to focus on targeting microRNAs implicated in heart disease as a strategy for therapeutic intervention BOULDER, CO, May 25, 2010 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics... View »

miRagen Therapeutics’ Chief Scientific Advisor to Give Plenary Lecture at Joint Meeting of the American Society for Clinical Investigation and the Association of American Physicians

Lecture to focus on role of microRNA biology in the progression of cardiovascular and muscle disease and the potential for therapeutic intervention BOULDER, Colo., April 23, 2010 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives... View »

RXi Pharmaceuticals and miRagen Therapeutics Announce Formation of Research Collaboration in the Field of microRNA

WORCESTER, Mass. & Boulder, Colo.–(BUSINESS WIRE)–April 12, 2010–Rxi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’... View »

miRagen Therapeutics Establishes Premier Scientific Advisory Board

Nobel Laureate Thomas R. Cech, Ph.D. among prestigious Board Members BOULDER, Colo., January 11, 2010 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced... View »